[HTML][HTML] 厄洛替尼致间质性肺病4 例并文献复习
吴小玲， 高广辉， 任胜祥， 周彩存 - Chinese Journal of Lung …, 2012 - ncbi.nlm.nih.gov
厄洛替尼是一种口服表皮生长因子受体酪氨酸激酶抑制剂（ epidermal growth factor receptor
tyrosine kinase inhibitor, EGFR-TKI）， 广泛应用于晚期非小细胞肺癌的治疗 …
tyrosine kinase inhibitor, EGFR-TKI）， 广泛应用于晚期非小细胞肺癌的治疗 …
厄洛替尼致间质性肺疾病的特点, 机制及防治
雷招宝 - 药物不良反应杂志, 2013 - cqvip.com
厄洛替尼为表皮生长因子受体酪氨酸激酶抑制剂(EGFR—TKI), 临床用于治疗非小细胞肺癌.
问质性肺疾病(ILD) 是厄洛替尼严重而少见的不良反应, 发生率为0.1%~ 4.8%, 病死率为0.8 …
问质性肺疾病(ILD) 是厄洛替尼严重而少见的不良反应, 发生率为0.1%~ 4.8%, 病死率为0.8 …
厄洛替尼治疗NSCLC 致急性间质性肺疾病的临床分析
王娜娜， 谭效锋， 沈虹， 吕元军， 杨书香， 潘文胜 - 实用肿瘤杂志, 2013 - cqvip.com
报道1 例厄洛替尼治疗非小细胞肺癌导致急性间质性肺疾病(interstitial lung disease, ILD),
并通过文献检索收集到24 例病例报道. 在这24 例病例中, 急性间质性肺疾病发生于服用厄洛替 …
并通过文献检索收集到24 例病例报道. 在这24 例病例中, 急性间质性肺疾病发生于服用厄洛替 …
吉非替尼与厄洛替尼致间质性肺病的临床特点分析
别志欣， 丁丽 - 中国药物警戒, 2017 - cqvip.com
目的探讨吉非替尼, 厄洛替尼致间质性肺病的临床特点. 方法在中国期刊全文数据库和万方
数据库中, 检索2004 年1 月至2016 年12 月发表的吉非替尼, 厄洛替尼致间质性肺病的文献报道 …
数据库中, 检索2004 年1 月至2016 年12 月发表的吉非替尼, 厄洛替尼致间质性肺病的文献报道 …
Four Cases of Interstitial Lung Disease Induced by Erlotinib and A Review of the Literatures.
X Wu, G Gao, S Ren, C Zhou - Chinese Journal of Lung …, 2012 - search.ebscohost.com
Erlotinib is an agent of oral epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors which are used for non-small cell lung cancer. Although this class of agents is …
inhibitors which are used for non-small cell lung cancer. Although this class of agents is …
Successful treatment with erlotinib after gefitinib-induced interstitial lung disease: a case report and literature review.
Y Koma, H Matsuoka, H Yoshimatsu… - International Journal of …, 2012 - europepmc.org
Gefitinib and erlotinib, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
(TKIs), are widely used anticancer drugs for patients with non-small cell lung cancer …
(TKIs), are widely used anticancer drugs for patients with non-small cell lung cancer …
Erlotinib achieved partial response in a non-small cell lung cancer patient with gefitinib-induced interstitial lung disease
Q Tian, L Chen - Case Reports in Oncology, 2011 - karger.com
Interstitial lung disease (ILD) induced by epidermal growth factor receptor tyrosine kinase
inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, is a rare but fatal complication of TKI …
inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, is a rare but fatal complication of TKI …
New-onset acute interstitial lung disease after treatment with erlotinib in a patient with metastatic squamous cell carcinoma of the lung
Abstract Erlotinib is a Human Epidermal Growth Factor Receptor Type 1/tyrosine kinase
(EGFR) inhibitor, which is used for non-small-cell lung cancer treatment. Erlotinib usually …
(EGFR) inhibitor, which is used for non-small-cell lung cancer treatment. Erlotinib usually …
Both gefitinib and erlotinib induced drug-related interstitial lung disease in a patient with pulmonary adenocarcinoma
KF Wang, CY Chang, SC Chang, YC Liu… - Journal of the …, 2013 - journals.lww.com
Abstract Treatment for non-small-cell lung cancer with gefitinib and erlotinib is efficacious.
However, while many studies have reported on gefitinib-related interstitial lung disease …
However, while many studies have reported on gefitinib-related interstitial lung disease …
[HTML][HTML] Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer
Abstract Background Erlotinib is a Human Epidermal Growth Factor Receptor Type
1/tyrosine kinase (EGFR) inhibitor which is used for non-small-cell lung cancer treatment …
1/tyrosine kinase (EGFR) inhibitor which is used for non-small-cell lung cancer treatment …